Results 31 to 40 of about 13,748 (197)

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability

Cancer Medicine, 2022
TRK fusions are rare but targetable mutations which occur across a wide variety of cancer types. We report the prevalence of approximately 0.7% for NTRK‐positive colorectal cancer (CRC) by genetically profiling 2519 colonic and rectal tumors.
Hui Wang, Zhi‐Wei Li, Qiuxiang Ou, Xue Wu, Misako Nagasaka, Yang Shao, Sai‐Hong Ignatius Ou, Yu Yang   +7 more
doaj   +1 more source

Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers

European Thyroid Journal, 2023
Objective: The aim of the study was to identify patients with NTRK fusion-positive or RET fusion/mutation-positive thyroid cancers, who could benefit from neurotrophic tyrosine kinase receptor (NTRK) or receptor tyrosine kinase (RET) inhibitors ...
Markus Eszlinger, Paul Stewardson, John B McIntyre, Adrian Box, Moosa Khalil, Martin Hyrcza, Konstantin Koro, Dean Ruether, Jiahui Wu, Ralf Paschke   +9 more
doaj   +1 more source

A Tumor-Agnostic NTRK (TRK) Inhibitor

Cell, 2019
Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.
Franklin W, Huang, Felix Y, Feng
openaire   +2 more sources

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations

BMC Pulmonary Medicine, 2023
Background The efficacy of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) patients harboring neurotrophin receptor kinase (NTRK) family mutations remains obscure. Methods The Zehir cohort from cBioPortal was used to analyze the
Xiaoling Shang, Wengang Zhang, Wenfei Han, Handai Xia, Ni Liu, Xiuwen Wang, Yanguo Liu   +6 more
doaj   +1 more source

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma

Frontiers in Oncology, 2020
IntroductionGlioblastoma multiforme (GBM) is the most common primary central nervous (CNS) system malignancy with a poor prognosis. The standard treatment for GBM is neurosurgical resection, followed by radiochemotherapy and adjuvant temozolomide ...
Yuekun Wang, Piaopiao Long, Yu Wang, Wenbin Ma   +3 more
doaj   +1 more source

Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report

Case Reports in Oncology, 2021
While neurotrophic tropomyosin receptor kinase (NTRK) fusions represent rare oncogenic drivers (<1% of solid cancers), the recent approval of NTRK inhibitors (larotrectinib and entrectinib) led to dramatic responses in patients with NTRK fusion ...
Tyler Lanman, Melanie Hayden Gephart, Nam Bui, Angus Toland, Seema Nagpal   +4 more
doaj   +1 more source

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics [PDF]

JCO Precision Oncology, 2018
Purpose Fusions that involve neurotrophic-tropomyosin receptor kinase ( NTRK) genes are known drivers of oncogenesis. Therapies that target these ultra-rare, constitutionally active NTRK fusions have been remarkably effective. Herein, we analyze the prevalence of the full array of NTRK alterations—fusions, mutations, copy number alterations, and ...
Okamura, Ryosuke, Boichard, Amélie, Kato, Shumei, Sicklick, Jason K, Bazhenova, Lyudmila, Kurzrock, Razelle   +5 more
openaire   +4 more sources

Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland

healthbook TIMES. Oncology Hematology, 2021
In May 2020, larotrectinib (Vitrakvi^®^) was approved as the first tumor-agnostic agent in Switzerland for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (*NTRK*) gene fusion.
Holger Moch, Gieri Cathomas, Milo Frattini, Wolfram Jochum, Erik Vassella, Laurence de Leval, Joachim Diebold, Christian Britschgi, Thomas McKee, Lukas Bubendorf   +9 more
doaj   +2 more sources

MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence In Situ Hybridization Positive Colorectal Carcinomas

Frontiers in Oncology, 2021
To gain insight into the clinicopathologic profile of colorectal carcinomas harboring oncogenic NTRK fusions based on eastern populations as well as make the best testing algorithm for the screen, we use pan-Trk immunohistochemistry (IHC), fluorescence ...
Yao Fu, Zheng Li, Fuping Gao, Jun Yang, Hongyan Wu, Biao Zhang, Xiaohong Pu, Xiangshan Fan   +7 more
doaj   +1 more source

Oncogenic fusions: Targeting NTRK

Critical Reviews in Oncology/Hematology
Non-Small Cell Lung Cancer (NSCLC) is responsible for the highest number of cancer-related deaths in the United States. Thankfully, advancements in the detection and targeting of gene mutations have greatly improved outcomes for many patients. One significant mutation driving oncogenesis in various cancers, including NSCLC, is the neurotrophic tyrosine
Garo Hagopian, Misako Nagasaka
openaire   +2 more sources